Intravenous B12 therapy is used in certain cases
It's a dual-action injection that targets hormones GLP-1 and GIP, which play a vital role in appetite regulation and blood sugar control
According to FDA prescribing information, nausea occurs in approximately 15-44% of patients depending on the specific agent and dose, with vomiting, diarrhea, constipation, and abdominal pain also frequently reported
Breakthrough Oral BPC-157 Formulas Clinicians have noted that the development of peptide therapeutics that are stable enough to withstand gastric juices could alter this dynamic
Retatrutide has not received marketing authorisation from the MHRA and is not approved for clinical use in the UK
Referral criteria vary by region, but these services offer intensive support for complex obesity